person · Reporting owner

Wills Robert James

Disclosed activity across 4 companies

Tapewire entity: 20237
SEC CIK: 0001634189

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alpha Cognition Inc.ACOG · Entity 6339	Director	August 21, 2026	August 24, 2026
Milestone Pharmaceuticals Inc.MIST · Entity 6561	Director	June 10, 2026	June 12, 2026
Oncternal Therapeutics, Inc.ONCT · Entity 89585	Director	June 20, 2024	June 24, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alpha Cognition Inc.

Report date August 21, 2026 · Filed August 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	32,241	Reported balance After 2026-08-21 transaction · row 1 1 source row Row 1 · 2026-08-21 · Purchase · Acquired 10,000 · Balance 32,241

Milestone Pharmaceuticals Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2036-06-10	Direct	77,000	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 77,000 · Balance 77,000 F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.

Oncternal Therapeutics, Inc.

Report date June 20, 2024 · Filed June 24, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2034-06-20	Direct	2,200	Reported balance After 2024-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-20 · Grant · Acquired 2,200 · Balance 2,200 F1: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CymaBay Therapeutics, Inc.

Report date March 22, 2024 · Filed March 22, 2024

Section 16 reporting ended · disclosed 2024-03-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-03-22 transaction · row 1 1 source row Row 1 · 2024-03-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2025-04-15	Direct	Reported balance After 2024-03-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-03-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.04 · Expires 2025-10-05	Direct	Reported balance After 2024-03-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-03-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2026-06-27	Direct	Reported balance After 2024-03-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-03-22 · Disposition to issuer · Disposed 9,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2027-04-26	Direct	Reported balance After 2024-03-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-03-22 · Disposition to issuer · Disposed 27,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2027-06-27	Direct	Reported balance After 2024-03-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-03-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.47 · Expires 2027-09-21	Direct	Reported balance After 2024-03-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-03-22 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.69 · Expires 2028-01-23	Direct	Reported balance After 2024-03-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-03-22 · Disposition to issuer · Disposed 16,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-01-28	Direct	Reported balance After 2024-03-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-03-22 · Disposition to issuer · Disposed 27,705 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2030-05-14	Direct	Reported balance After 2024-03-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-03-22 · Disposition to issuer · Disposed 49,245 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.78 · Expires 2031-01-25	Direct	Reported balance After 2024-03-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-03-22 · Disposition to issuer · Disposed 32,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2032-01-24	Direct	Reported balance After 2024-03-22 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2024-03-22 · Disposition to issuer · Disposed 67,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2033-01-24	Direct	Reported balance After 2024-03-22 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2024-03-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.85 · Expires 2034-01-23	Direct	Reported balance After 2024-03-22 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2024-03-22 · Disposition to issuer · Disposed 14,010 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.

F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 21, 2026 Filed Aug 24, 2026 18:52 UTC	Alpha Cognition Inc. ACOG · Entity 6339	PurchaseCommon Shares	10,000	$9.62	$96,200.00	Disclosure SEC source: 0000912282-26-001153 · form4.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,241 Read SEC document
June 10, 2026 Filed Jun 12, 2026 20:15 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantStock Option (right to buy) · Derivative	77,000	$0.00 Strike: $1.22	$0.00	Disclosure SEC source: 0001634189-26-000002 · form4-06122026_040601.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document
January 14, 2026 Filed Jan 16, 2026 21:21 UTC	Alpha Cognition Inc. ACOG · Entity 6339	GrantCommon Share Options · Derivative	8,437	$0.00 Strike: $6.56	$0.00	Disclosure SEC source: 0000912282-26-000070 · form4.xml · derivative · entry 2 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,437 Underlying: Common Shares · 8,437 shares Expires 2036-01-14 F2 · derivative.exercise_date: The options will vest one year from date of grant. Read SEC document
January 14, 2026 Filed Jan 16, 2026 21:21 UTC	Alpha Cognition Inc. ACOG · Entity 6339	GrantCommon Shares	7,241	$0.00	$0.00	Disclosure SEC source: 0000912282-26-000070 · form4.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,241 F1 · shares: Restricted stock units that vest one year from date of grant. Read SEC document
August 18, 2025 Filed Aug 21, 2025 16:36 UTC	Alpha Cognition Inc. ACOG · Entity 6339	PurchaseCommon Stock	15,000	$8.49	$127,327.50	Disclosure SEC source: 0000912282-25-000893 · form4.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · kind: Open market purchase. F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.15 to $8.86 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
July 11, 2025 Filed Jul 15, 2025 20:15 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantSeries B Common Warrants (right to buy) · Derivative	50,000	Not disclosed Strike: $1.88	Not disclosed	Disclosure SEC source: 0001415889-25-019774 · form4-07152025_040719.xml · derivative · entry 3 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2030-07-11 F1 · price: The reported securities are included within 50,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 50,000 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 11, 2025 Filed Jul 15, 2025 20:15 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantSeries A Common Warrants (right to buy) · Derivative	50,000	Not disclosed Strike: $1.50	Not disclosed	Disclosure SEC source: 0001415889-25-019774 · form4-07152025_040719.xml · derivative · entry 2 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2026-07-11 F1 · price: The reported securities are included within 50,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 50,000 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 11, 2025 Filed Jul 15, 2025 20:15 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantCommon Shares	50,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-019774 · form4-07152025_040719.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 F1 · price: The reported securities are included within 50,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 50,000 shares of common stock. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:19 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $1.75	$0.00	Disclosure SEC source: 0001415889-25-016935 · form4-06122025_040616.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2025, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document
April 07, 2025 Filed Apr 10, 2025 01:44 UTC	Alpha Cognition Inc. ACOG · Entity 6339	GrantDirector Stock Option (Right to Buy) · Derivative	30,019	$0.00 Strike: $4.43	$0.00	Disclosure SEC source: 0000912282-25-000390 · form4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,019 Underlying: Common Shares · 30,019 shares Expires 2025-04-07 F1 · derivative.exercise_date: The options will vest over 24 months, with 12.5% vesting on the grant date and remainder to vest 12.5% per quarter thereafter. Read SEC document
August 28, 2024 Filed Aug 29, 2024 20:15 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $1.45	$0.00	Disclosure SEC source: 0001415889-24-022532 · form4-08292024_040801.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2034-08-28 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on September 28, 2024, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document
June 20, 2024 Filed Jun 24, 2024 16:05 UTC	Oncternal Therapeutics, Inc. ONCT · Entity 89585	GrantStock Options · Derivative	2,200	$0.00 Strike: $8.10	$0.00	Disclosure SEC source: 0000950170-24-076700 · ownership.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 2,200 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. Read SEC document
April 08, 2024 Filed Apr 10, 2024 20:38 UTC	Oncternal Therapeutics, Inc. ONCT · Entity 89585	PurchaseCommon Stock	3,086	$8.96	$27,654.57	Disclosure SEC source: 0001209191-24-005283 · doc4.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: The common stock purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, but the reporting person previously paid the Issuer the full amount of the profit realized in connection with the short swing transaction. No further amounts are required to be disgorged. F2 · price: The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $8.76 to $9.00. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above. Read SEC document
March 28, 2024 Filed Apr 1, 2024 19:00 UTC	Oncternal Therapeutics, Inc. ONCT · Entity 89585	PurchaseCommon Stock	6,914	$8.48	$58,602.37	Disclosure SEC source: 0001209191-24-005154 · doc4.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,914 F1 · shares: The Reporting Person's common stock purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 980 shares at a weighted average price per share of $8.1548, with the sale of 980 shares of common stock at a price per share of $9.04 on February 23, 2024. The Reporting Person has agreed to pay the issuer $867.51, representing the full amount of the profit realized in connection with the short-swing transaction. F2 · price: The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $8.095 to $9.00. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	14,010	Not disclosed Strike: $22.85	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 14 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,010 shares Expires 2034-01-23 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	25,000	Not disclosed Strike: $7.80	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 13 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2033-01-24 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	67,000	Not disclosed Strike: $2.94	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 12 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,000 shares Expires 2032-01-24 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	32,000	Not disclosed Strike: $5.78	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 11 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,000 shares Expires 2031-01-25 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	49,245	Not disclosed Strike: $4.05	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 10 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,245 shares Expires 2030-05-14 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	27,705	Not disclosed Strike: $8.43	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 9 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,705 shares Expires 2029-01-28 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	16,000	Not disclosed Strike: $11.69	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 8 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2028-01-23 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	7,500	Not disclosed Strike: $7.47	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 7 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2027-09-21 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $5.50	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 6 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-06-27 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	27,000	Not disclosed Strike: $3.48	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 5 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,000 shares Expires 2027-04-26 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	9,000	Not disclosed Strike: $1.72	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 4 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2026-06-27 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	25,000	Not disclosed Strike: $2.04	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 3 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-10-05 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	18,000	Not disclosed Strike: $5.90	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · derivative · entry 2 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2025-04-15 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:55 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerCommon Stock	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-035448 · ownership.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes. Read SEC document
February 23, 2024 Filed Feb 27, 2024 17:02 UTC	Oncternal Therapeutics, Inc. ONCT · Entity 89585	SaleCommon Stock	980	$9.04	$8,859.20	Disclosure SEC source: 0001209191-24-004015 · doc4.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The shares of common stock were sold directly to another director of the Issuer, David F. Hale, and an affiliated entity of Mr. Hale in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024. F1 · price: The shares of common stock were sold directly to another director of the Issuer, David F. Hale, and an affiliated entity of Mr. Hale in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024. Read SEC document
January 24, 2024 Filed Jan 26, 2024 18:20 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	14,010	$0.00 Strike: $22.85	$0.00	Disclosure SEC source: 0001062993-24-001422 · form4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,010 Underlying: Common Stock · 14,010 shares Expires 2034-01-23 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2024. Read SEC document
June 28, 2023 Filed Jun 30, 2023 16:00 UTC	Oncternal Therapeutics, Inc. ONCT · Entity 89585	GrantStock Options · Derivative	25,000	$0.00 Strike: $0.36	$0.00	Disclosure SEC source: 0001209191-23-040282 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-28 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:23 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $3.86	$0.00	Disclosure SEC source: 0001209191-23-035844 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 7, 2023, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document
January 25, 2023 Filed Jan 27, 2023 16:33 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $7.80	$0.00	Disclosure SEC source: 0001062993-23-001496 · form4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-01-24 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2023. Read SEC document
October 19, 2022 Filed Oct 21, 2022 23:03 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	PurchaseCommon Shares	15,000	$4.93	$73,950.00	Disclosure SEC source: 0001209191-22-054328 · doc4.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.89 to $4.9494 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
July 05, 2022 Filed Aug 11, 2022 22:02 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $6.07	$0.00	Disclosure SEC source: 0001209191-22-045472 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2032-07-05 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on August 5, 2022, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document
June 16, 2022 Filed Jun 17, 2022 18:00 UTC	Oncternal Therapeutics, Inc. ONCT · Entity 89585	GrantStock Options · Derivative	25,000	$0.00 Strike: $1.08	$0.00	Disclosure SEC source: 0001209191-22-038033 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. Read SEC document
January 25, 2022 Filed Jan 27, 2022 16:51 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	67,000	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001062993-22-001690 · form4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2032-01-24 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2022. Read SEC document
June 14, 2021 Filed Jul 29, 2021 21:34 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $5.54	$0.00	Disclosure SEC source: 0001209191-21-048563 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 14, 2021, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document
May 25, 2021 Filed May 27, 2021 18:12 UTC	Oncternal Therapeutics, Inc. ONCT · Entity 89585	GrantStock Options · Derivative	25,000	$0.00 Strike: $5.14	$0.00	Disclosure SEC source: 0001209191-21-036324 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
January 26, 2021 Filed Jan 28, 2021 15:01 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	32,000	$0.00 Strike: $5.78	$0.00	Disclosure SEC source: 0001333277-21-000026 · edgar.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2021. Read SEC document
October 01, 2020 Filed Oct 5, 2020 22:02 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $7.10	$0.00	Disclosure SEC source: 0001209191-20-053842 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2030-10-01 F1 · derivative.exercise_date: This option will vest in equal monthly installments, beginning on November 1, 2020, over a period of three years, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document
June 11, 2020 Filed Jun 12, 2020 16:42 UTC	Oncternal Therapeutics, Inc. ONCT · Entity 89585	GrantStock Options · Derivative	15,000	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001209191-20-036309 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
June 11, 2020 Filed Jul 31, 2020 21:06 UTC Amendment	Oncternal Therapeutics, Inc. ONCT · Entity 89585	GrantStock Option · Derivative	15,000	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001209191-20-044386 · doc4a.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-11 F1 · shares: The original Form 4 reported the acquisition of the Stock Options in the "D" column of Column 5. This amendment is being filed to correctly report the acquisition of the Stock Options in the "A" column of Column 5. F2 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
May 15, 2020 Filed May 19, 2020 17:19 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (Right to Buy) · Derivative	49,245	$0.00 Strike: $4.05	$0.00	Disclosure SEC source: 0001209191-20-030592 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,245 Underlying: Common Stock · 49,245 shares Expires 2030-05-14 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on January 31, 2020, subject to the Reporting Person's continuous service to the Issuer as of each such date. Read SEC document
September 12, 2019 Filed Sep 16, 2019 17:44 UTC	Oncternal Therapeutics, Inc. ONCT · Entity 89585	GrantStock Option · Derivative	30,000	$0.00 Strike: $5.76	$0.00	Disclosure SEC source: 0001209191-19-049698 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-09-12 F1 · derivative.exercise_date: One thirty-sixth of each Effective Date Award and each Initial Award shall vest and become exercisable in substantially equal installments on each monthly anniversary of the date of grant, so that the options subject to each such type of award shall be fully vested on the three-year anniversary of the date of grant, subject to the Reporting Persons continued service on the Board through each such vesting date. Read SEC document
September 12, 2019 Filed Jul 31, 2020 21:06 UTC Amendment	Oncternal Therapeutics, Inc. ONCT · Entity 89585	GrantStock Options · Derivative	30,000	$0.00 Strike: $5.76	$0.00	Disclosure SEC source: 0001209191-20-044389 · doc4a.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-09-12 F1 · shares: The original Form 4 reported the acquisition of the Stock Options in the "D" column of Column 5. This amendment is being filed to correctly report the acquisition of the Stock Options in the "A" column of Column 5. F2 · derivative.exercise_date: One thirty-sixth of each Effective Date Award and each Initial Award shall vest and become exercisable in substantially equal installments on each monthly anniversary of the date of grant, so that the options subject to each such type of award shall be fully vested on the three-year anniversary of the date of grant, subject to the Reporting Persons continued service on the Board through each such vesting date. Read SEC document
January 29, 2019 Filed Jan 31, 2019 17:24 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	27,705	$0.00 Strike: $8.43	$0.00	Disclosure SEC source: 0001333277-19-000025 · edgar.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,705 Underlying: Common Stock · 27,705 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2019. Read SEC document
June 26, 2018 Filed Jun 26, 2018 11:21 UTC	Oncternal Therapeutics, Inc. GTXI · Entity 89585	PurchaseCommon Stock	5,000	$16.75	$83,750.00	Disclosure SEC source: 0001179110-18-009039 · edgar.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,344 Read SEC document
January 24, 2018 Filed Jan 26, 2018 17:47 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	16,000	$0.00 Strike: $11.69	$0.00	Disclosure SEC source: 0001333277-18-000033 · edgar.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly beginning January 1, 2018. Read SEC document
January 01, 2018 Filed Jan 3, 2018 18:27 UTC	Oncternal Therapeutics, Inc. GTXI · Entity 89585	GrantEmployee Stock Option (Right to Buy) · Derivative	65,000	$0.00 Strike: $12.71	$0.00	Disclosure SEC source: 0001179110-18-000407 · edgar.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-12-31 F1 · derivative.exercise_date: The option vests and is exercisable in 3 equal annual installments beginning January 1, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.